← All trials
NCT05796557
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 13, 2023
- Primary completion
- Apr 1, 2025
- Completion date
- Sep 1, 2025
- First posted
- Apr 3, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- University of WisconsinCollaborator
- Columbia UniversityCollaborator
- Duke UniversityCollaborator
- Emory UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of IowaCollaborator
- University of RochesterCollaborator
- University of UtahCollaborator
- Virginia Commonwealth UniversityCollaborator
- Cornell UniversityCollaborator
- Yale UniversityOverall official - principal investigator
- Yale UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.